Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.43 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.43 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.43 |
| ▸ | FPR1 | P21462 | 2/20 | 0.42 |
| ▸ | FPR2 | P25090 | 2/20 | 0.42 |
| ▸ | FNTA | P49354 | 7/20 | 0.41 |
| ▸ | FNTB | P49356 | 7/20 | 0.41 |
| ▸ | PGGT1B | P53609 | 5/20 | 0.41 |
| ▸ | LTA4H | P09960 | 2/20 | 0.41 |
| ▸ | TACR3 | P29371 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1695338 | 0.93 | FOLH1 (0.39) | ANPEPRNPEPDNPEPFPR1FPR2 | |
| SCHEMBL258735 | 0.89 | ANPEP (0.44) | ANPEPRNPEPDNPEPFNTAFNTB | |
| SCHEMBL9242775 | 0.88 | ANPEP (0.43) | ANPEPRNPEPDNPEPLTA4H | |
| SCHEMBL1128048 | 0.87 | ANPEP (0.50) | ANPEPRNPEPDNPEPFNTAFNTB | |
| Acetic Acid SCHEMBL15201184 | 0.85 | ANPEP (0.48) | ANPEPRNPEPDNPEPFNTAFNTB | |
| Phenylalanine SCHEMBL304849 | 0.82 | LTA4H (0.50) | FPR1FPR2FNTAFNTBPGGT1B | |
| Dl-Phenylalanine SCHEMBL7222094 | 0.82 | LTA4H (0.50) | FPR1FPR2FNTAFNTBPGGT1B | |
| SCHEMBL9623604 | 0.80 | FPR1 (0.45) | ANPEPFPR1FPR2FNTAFNTB | |
| SCHEMBL9623606 | 0.80 | FPR1 (0.45) | ANPEPFPR1FPR2FNTAFNTB | |
| SCHEMBL21722622 | 0.80 | ACE (0.43) | FPR1FPR2FNTAFNTBLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 504 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492367-B2 | Sensor chip capable of culturing cells and of analyzing cell-derived substance, and cell activity quantitative analysis method using the same | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2025-12-09 | — | — | US | claimed |
| US-20250243445-A1 | BIOSENSING CHIP TO ANALYZE CELL-DERIVED MATERIALS DURING CELL CULTURE, AND METHOD FOR QUANTITATIVE ANALYSIS OF CELL ACTIVITY USING THE SAME | AJOU UNIVERSITY INDUSTRY-ACDEMIC COOPERATION FOUNDATION (KR) | 2025-07-31 | — | — | US | claimed |
| US-12274704-B2 | 9,11-secosteroids and the use of 9,11-secosteroids in preparing pharmaceutical compositions for inhibiting inflammation | CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY (TW) | 2025-04-15 | — | — | US | claimed |
| CN-111330023-B | Magnetic nano composite material and preparation method and application thereof | 中国科学院宁波材料技术与工程研究所慈溪生物医学工程研究所 | 2023-01-31 | — | — | CN | claimed |
| CN-109416357-B | Devices, systems, and methods for detecting an analyte in a bodily fluid sample comprising a plurality of cells | 西门子医疗系统荷兰有限公司 | 2022-07-15 | — | — | CN | claimed |
| US-11125744-B2 | Device, system and method for detecting an analyte in a body fluid sample containing a plurality of cells | SIEMENS HEALTHINEERS NEDERLAND B.V. (NL) | 2021-09-21 | — | — | US | claimed |
| EP-3826659-A1 | USE OF IMMUNOMODULATORS TO CONTROL INFECTION AND STIMULATE HEALING IN NORMAL AND DIABETIC WOUNDS | Rush University Medical Center (US) | 2021-06-02 | — | — | EP | claimed |
| US-10872410-B2 | Methods and apparatus for assessing immune system activity and therapeutic efficacy | ANIMANTIS, LLC (US) | 2020-12-22 | — | — | US | claimed |
| EP-3479119-B1 | METHOD FOR DETECTING AN ANALYTE IN A BODY FLUID SAMPLE CONTAINING A PLURALITY OF CELLS | KONINKLIJKE PHILIPS NV (NL) | 2020-08-12 | — | — | EP | claimed |
| CN-111330023-A | Magnetic nano composite material and preparation method and application thereof | 中国科学院宁波工业技术研究院慈溪生物医学工程研究所 | 2020-06-26 | — | — | CN | claimed |
| EP-2324857-A1 | Imaging agents for early detection of cardiovascular plaque | The General Hospital Corporation (US) | 2011-05-25 | — | — | EP | claimed |
| CN-101516190-A | Methods for reducing inflammatory mediator release and peptides useful therefor | BIOMARCK PHARMACEUTICALS LTD (US) | 2009-08-26 | — | — | CN | claimed |
| US-20090203620-A1 | METHODS FOR ATTENUATING RELEASE OF INFLAMMATORY MEDIATORS AND PEPTIDES USEFUL THEREIN | BIOMARCK PHARMACEUTICALS LTD. | 2009-08-13 | — | — | US | claimed |
| CN-101500593-A | Methods for regulating inflammatory mediators and peptides useful therein | BIOMARCK PHARMACEUTICALS LTD (US) | 2009-08-05 | — | — | CN | claimed |
| US-7544772-B2 | Methods for regulating inflammatory mediators and peptides useful therein | BIOMARCK PHARMACEUTICALS, LTD. (US) | 2009-06-09 | — | — | US | claimed |
| EP-2053915-A2 | METHODS FOR ATTENUATING RELEASE OF INFLAMMATORY MEDIATORS AND PEPTIDES USEFUL THEREIN | Biomarck Pharmaceuticals, Ltd. (US) | 2009-05-06 | — | — | EP | claimed |
| EP-1991250-A2 | METHODS FOR REGULATING INFLAMMATORY MEDIATORS AND PEPTIDES USEFUL THEREIN | Biomarck Pharmaceuticals, Ltd. (US) | 2008-11-19 | — | — | EP | claimed |
| WO-2008014414-A2 | METHODS FOR ATTENUATING RELEASE OF INFLAMMATORY MEDIATORS AND PEPTIDES USEFUL THEREIN | BIOMARCK PHARMACEUTICALS, LTD. (US) | 2008-01-31 | — | — | WO | claimed |
| WO-2007103368-A2 | METHODS FOR REGULATING INFLAMMATORY MEDIATORS AND PEPTIDES USEFUL THEREIN | BIOMARCK PHARMACEUTICALS, LTD. (US) | 2007-09-13 | — | — | WO | claimed |
| US-20060217307-A1 | Methods for regulating inflammatory mediators and peptides useful therein | BIOMARCK PHARMACEUTICALS, LTD. | 2006-09-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12274704-B2 | 9,11-secosteroids and the use of 9,11-secosteroids in preparing pharmaceutical compositions for inhibiting inflammation | HSD11B1, HSD11B2, CYP4A11 | ANPEP 2363/4885RNPEP 2224/4885DNPEP 3386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.